Relugolix (TAK-385)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Relugolix (TAK-385), covering 2019-03-22 to 2019-03-22. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids [Phase 3]